Vasoactive properties of bimatoprost in isolated porcine ciliary arteries

被引:9
作者
Allemann, R [1 ]
Flammer, J [1 ]
Haefliger, IO [1 ]
机构
[1] Univ Eye Clin Basel, Lab Ocular Pharmacol & Physiol, CH-4012 Basel, Switzerland
关键词
ciliary artery; latanoprost; travoprost; unoprostone; ocular blood flow; glaucoma; intraocular pressure;
D O I
10.1055/s-2003-38167
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: To investigate the vasoactive effect of bimatoprost (Lumigan(R)), a new topical ocular hypotensive agent, in isolated porcine ciliary arteries. Material and methods: Arteries were placed in a myograph system to measure isometric forces. Quiescent vessels as well as vessels pre-contracted with either 10 nM endothelin-1 or 100 mM potassium chloride (KCl) were exposed, in a cumulative manner, to increasing concentrations (0.1 nM-0.1 mM) of bimatoprost (dissolved in ethanol). in quiescent vessels, results were expressed in percent of 100 mM KCl-induced contraction. In endothelin-1-pre-contracted vessels, results were expressed in percent of the maximal contraction induced by endothelin-1. In KCl-pre-contracted vessels, results were expressed in percent of the plateau contraction reached 30 minutes after 100 mM KCl application. Results: Bimatoprost induced a significant (p < 0.05 - 0.001) vasoconstriction at concentrations equal to or higher than 0.1 mu M in quiescent vessels (0.1 mM: 73 +/- 12%). In KCl-pre-contracted vessels, at concentrations higher than 1 mu M bimatoprost induced significant (p < 0.05 - 0.01) contractions (0.1 mM: 67 +/- 17%). In endothelin-1-pre-contracted vessels, bimatoprost also induced significant (p<0.05-0.001) contractions at concentrations above 10 mu M (0.1 mM: 17 +/- 8%). Conclusions: The present study indicates that bimatoprost appears to have, in vitro, some vasoactive properties in porcine ciliary arteries. The question whether Lumigan(R) has an influence on ocular blood flow needs to be further investigated.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 9 条
[1]   Mechanism of action of bimatoprost (Luminan™) [J].
Brubaker, RF .
SURVEY OF OPHTHALMOLOGY, 2001, 45 :S347-S351
[2]   Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs [J].
Eisenberg, DL ;
Toris, CB ;
Camras, CB .
SURVEY OF OPHTHALMOLOGY, 2002, 47 :S105-S115
[3]  
Flammer J, 1999, J GLAUCOMA, V8, P212
[4]   The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist [J].
Maxey, KM ;
Johnson, JL ;
LaBrecque, J .
SURVEY OF OPHTHALMOLOGY, 2002, 47 :S34-S40
[5]   Bimatoprost and its free acid are prostaglandin FP receptor agonists [J].
Sharif, NA ;
Williams, GW ;
Kelly, CR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 432 (2-3) :211-213
[6]  
Weinreb RN, 1997, INVEST OPHTH VIS SCI, V38, P2772
[7]   The pharmacology of bimatoprost (Lumigan™) [J].
Woodward, DF ;
Krauss, AHP ;
Chen, J ;
Lai, RK ;
Spada, CS ;
Burk, RM ;
Andrews, SW ;
Shi, L ;
Liang, Y ;
Kedzie, KM ;
Chen, R ;
Gil, DW ;
Kharlamb, A ;
Archeampong, A ;
Ling, J ;
Madhu, C ;
Ni, J ;
Rix, P ;
Usansky, J ;
Usansky, H ;
Weber, A ;
Welty, D ;
Yang, W ;
Tang-Liu, DDS ;
Garst, ME ;
Brar, B ;
Wheeler, LA ;
Kaplan, LJ .
SURVEY OF OPHTHALMOLOGY, 2001, 45 :S337-S345
[8]   Prostaglandin F-2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species [J].
Yousufzai, SYK ;
Ye, Z ;
AbdelLatif, AA .
EXPERIMENTAL EYE RESEARCH, 1996, 63 (03) :305-310
[9]  
Zhi P, 1999, INVEST OPHTH VIS SCI, V40, P1015